BiotechTube

Pasireotide long acting release formulation

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acromegaly

Conditions

Acromegaly

Trial Timeline

— → —

NCT ID
NCT01995734

About Pasireotide long acting release formulation

Pasireotide long acting release formulation is a pre-clinical stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT01995734. Target conditions include Acromegaly.

What happened to similar drugs?

13 of 20 similar drugs in Acromegaly were approved

Approved (13) Terminated (1) Active (7)
🔄Pasireotide LARNovartisPhase 3
🔄Octreotide acetate 30 mg suspensionNovartisPhase 3
✅Sandostatin LAR + pegvisomant + cabergolineNovartisApproved
✅Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved
✅Sandostatin LARNovartisApproved
🔄Pasireotide + OctreotideNovartisPhase 3
✅Sandostatin (Octreotide Acetate)NovartisApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01995734Pre-clinicalCompleted

Competing Products

20 competing products in Acromegaly

See all competitors
ProductCompanyStageHype Score
AlesseNovartisPhase 2
31
ONO-5788 + ONO-5788 Placebo + OctreotideOno PharmaceuticalPhase 1
21
ONO-5788 + [14C]-ONO-5788Ono PharmaceuticalPhase 1
29
Pasireotide LARNovartisPhase 3
40
Octreotide acetate 30 mg suspensionNovartisPhase 3
40
Sandostatin LAR + pegvisomant + cabergolineNovartisApproved
43
Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved
43
Sandostatin LARNovartisApproved
43
Pasireotide + OctreotideNovartisPhase 3
40
Sandostatin (Octreotide Acetate)NovartisApproved
39
Octreotide acetateNovartisApproved
35
octreotide FluidCrystal® injection depotNovartisPhase 2
35
Octreotide LARNovartisPhase 3
40
Octreotide LARNovartisPhase 3
40
PasireotideNovartisPhase 2
35
Pasireotide LAR 60 mg + PegvisomantNovartisApproved
39
OctreotideNovartisApproved
43
Octreotide LAR 30 MG InjectionNovartisApproved
43
Pasireotide LARNovartisPhase 2
35
Pasireotide (SOM230), Octreotide (Sandostatin)NovartisPhase 2
35